Commencement of flash glucose monitoring is associated with a decreased rate of depressive disorders among persons with diabetes (FLARE-NL7)

Julia J Bakker,1 Annel Lameijer,1 Jose L Flores Guerrero,2 Henk J G Bilo,3,4 Peter R van Dijk

ABSTRACT

Introduction Depressive disorders are more common among persons with diabetes, as compared with persons without diabetes. The burden of glucose management is known to associate with depressive symptoms. This study aims to assess the effects of commencement of FreeStyle Libre flash glucose monitoring (FSL-FGM) on the mental health status of persons with diabetes.

Research design and methods Post-hoc analysis of data from a 1-year prospective nationwide FSL-FGM registry. Participants who used FSL-FGM for 12 months and completed the 12-item Short Form Health Survey version 2 (SF-12v2) questionnaires at baseline, 6 and 12 months were included. An SF-12v2 Mental Component Score (MCS) of ≤45 was used as a cut-off to discriminate between persons with and without a depressive disorder.

Results A total of 674 patients were included with a mean age of 48.2 (±15.8) years, 51.2% men, 78.2% type 1 diabetes and baseline HbA1c 62.8 (±13.4) mmol/mol (7.9±1.2%). At baseline, 235 (34.9%) persons had an SF-12 MCS ≤45 while after 6 and 12 months these numbers decreased: 202 (30.0%, p<0.01) and 173 (25.7%, p<0.01). Overall, MCS improved from 48.5 at baseline to 50.7 after 6 months and 51.3 after 12 months. In multivariable regression analysis, age and MICS at baseline were associated with improvement of MCS after 12 months of FSL-FGM use.

Conclusions This analysis suggests that use of FSL-FGM is associated with a decreased rate of depressive disorders among persons with diabetes. Future studies are needed to corroborate these findings.

INTRODUCTION

With flash glucose monitoring (FGM) persons with diabetes mellitus (DM) can measure glucose concentrations in the interstitial fluid. The FreeStyle Libre (FSL; Abbott Diabetes Care) FGM is a factory-calibrated FGM that replaces fingerprick testing by intermittent scanning of the sensor. The use of FSL-FGM results in positive effects on glycemic control and quality of life.1–5

The prevalence of depression is reported to be 12% in persons with type 1 DM and 28% in persons with type 2 DM.6–7 As compared with persons without diabetes, this is three-fold (for type 1 DM) and twofold (for type 2 DM) higher.6 Adults with diabetes and comorbid depression have worse glycemic control and more microvascular and macrovascular complications than those not diagnosed with a depressive disorder.8–9 Intensive self-management, including (painful) fingerpricks, and insufficient insight in causes of variable glucose levels are determinants of depression in DM.10 As FSL-FGM use alleviates the burden of diabetes self-management and provides insights in glucose excursions,
its use may lead to improved mental well-being and lower rates of depressive disorders.

Longitudinal studies evaluating the effects of FSL-FGM initiation on depression and diabetes-related distress are scarce and show conflicting outcomes. Deshmukh et al. showed reduced diabetes-related distress during 7 months of FSL-FGM use by persons with diabetes (97% type 1DM). In another prospective cohort study, a decrease in diabetes-related distress after 12 weeks of use of FSL-FGM was described in youngsters with type 1DM. Tyndall et al. demonstrated improvements with regard to total diabetes distress, regimen-related distress and emotional distress among persons with type 1DM using FSL-FGM, although they paradoxically noticed an increase in depression and anxiety scores on the Hospital Anxiety and Depression Scale (HADS).

Given the negative impact of depression on quality of life, the potential beneficial effects of FSL-FGM on depressive disorders and conflicting (short-term) outcomes of studies evaluating the impact of FGM on mental health, the present study aims to provide more insight into the effects of long-term use of FSL-FGM on mental well-being and depressive disorder rates.

METHODS

Study design and patient selection

This is a post-hoc analyses of data from the ‘FLAsh monitor REgistry in the NetherLands’ (FLARE-NL). The FLARE-NL registry had a prospective, observational design (study period June 2016–July 2017) and aimed to assess the effects of FSL-FGM on daily life. Detailed information concerning the 1-year outcomes of the FLARE-NL registry has been published earlier. In brief, adults (≥18 years) with DM using insulin were eligible for participation in the FLARE-NL registry; 1365 persons were included. For the present post-hoc analyses, only persons who started FSL-FGM, continued to use it for 12 months and completed the 12-Item Short Form Health Survey version 2 (SF-12v2) questionnaires at baseline, 6 and 12 months (n=674) were included. Based on previous studies, a Mental Component Score (MCS) of ≤45 was used as a cut-off to indicate the presence of a depressive disorder.

Outcomes

Primary outcome was the difference in the rate of persons with an SF-12 MCS ≤45 (indicative of a depressive disorder) between baseline and 6 and 12 months after FSL-FGM initiation. Furthermore, changes in MCS over time were investigated for the total population as well as different subgroups. Finally, the association between the difference in MCS over the study period and other variables was assessed.

Study procedures

After informed consent was obtained, the healthcare provider filled out the data necessary for the registry and study participants filled out online questionnaires regarding quality of life and disease burden, including the SF-12v2. The SF-12v2 questionnaire measures eight health dimensions: physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. The Physical Component Summary and the MCS are two subscales derived from the SF-12v2. Glycemic control during follow-up was assessed using self-reported most recent HbA1c values and the number of hypoglycemas (glucose <3 mmol/L in the past 6 months).

Statistical analysis

To determine if variables were normally distributed, histograms and Q–Q plots were used. Categorical data were expressed as n (%), normally distributed data as means±SD and skewed distributed data as median with IQR. Pairwise t-test was used to compare the MCS after 6 and 12 months with baseline values. P values were adjusted with the Holm method for multiple comparison. A two-sided p<0.05 was considered statistically significant. Univariable linear regression analyses were performed to investigate the association between the difference in MCS over the 12-month study period and other variables. Next, multivariable linear regression analysis was performed to investigate associations between the difference in MCS over the study period as dependent variable and multiple independent covariates (age, sex, baseline HbA1c, number of hypoglycemic episodes and microvascular and macrovascular complications). Data were analyzed with R Statistical Software (V.4.0.3).

RESULTS

A total of 674 persons were included in the study. As presented in table 1, 345 (51.2%) were men and mean age was 48.2 (±15.8) years. Most persons (527 (78.2%)) had type 1DM. Baseline HbA1c was 62.8 (±13.4) mmol/mol (7.9±1.2%). Microvascular complications were present in 230 (34.1%) and macrovascular complications in 86 (12.8%) persons.

Changes in MCS are presented in table 2. Baseline MCS was 48.5 and improved to 50.7 after 6 months and 51.3 after 12 months. Scores improved over time for both sexes, although baseline MCS was lower among women. At baseline, 235 (34.9%) participants had an SF-12 MCS ≤45, indicative of depressive disorder, which decreased to 202 (30.0%) after 6 months and 173 (25.7%) after 12 months (p<0.01). For men as well as women with a baseline MCS ≤45, scores improved after 6 and 12 months compared with baseline. The MCS after 12 months in these subgroups increased to 45.2±9.2 and 43.6±10.4 for men and women, respectively. Furthermore, improvement of MCS was observed in subgroups with type 1DM and in all HbA1c subgroups (≤53, >53 and >64 mmol/mol).
TABLE 1 Baseline characteristics of all participants (n=674)

| Characteristic                              | Number (Percentage) |
|---------------------------------------------|---------------------|
| Male sex, n (%)                             | 345 (51.2)          |
| Age, years                                  | 48.2 (15.6)         |
| HbA1c, mmol/mol                             | 62.8 (13.4)         |
| HbA1c, %                                    | 7.9 (1.2)           |
| Type of diabetes                            |                     |
| Type 1 DM, n (%)                            | 527 (78.2)          |
| Type 2 DM, n (%)                            | 98 (14.5)           |
| LADA, n (%)                                 | 37 (5.5)            |
| MODY, n (%)                                 | 3 (0.4)             |
| Other forms, n (%)                          | 9 (1.3)             |
| Complications                               |                     |
| Microvascular complications, n (%)          | 230 (34.1)          |
| Neuropathy, n (%)                           | 88 (13.1)           |
| Albuminuria, n (%)                          | 110 (16.3)          |
| Retinopathy, n (%)                          | 100 (14.8)          |
| Macrovascular complications, n (%)          | 86 (12.8)           |
| Angina pectoris, n (%)                      | 15 (2.2)            |
| Myocardial infarction, n (%)                | 22 (3.3)            |
| PCI, n (%)                                  | 30 (4.5)            |
| CABG, n (%)                                 | 23 (3.4)            |
| TIA, n (%)                                  | 17 (2.5)            |
| CVA, n (%)                                  | 14 (2.1)            |
| Peripheral arterial disease, n (%)          | 32 (4.7)            |
| Diabetes-related hospital admissions past 12 months, yes, n (%) | 74 (11.0) |
| Diabetes-related work absenteeism past 6 months, yes, n (%) | 25 (3.7) |
| Estimated strips use per day                | 2.0 (0–5.5)         |
| Presence of any hypoglycemic events in past 6 months, n (%) | 622 (92.3) |
| Estimated or measured number of hypoglycemic events in past 6 months | 40.0 (15–80) |
| Therapy                                     |                     |
| Insulin monotherapy, n (%)                  | 575 (85.6)          |
| OBGLD, n (%)                                | 1 (0.1)             |
| Insulin and OBGLD, n (%)                    | 96 (14.3)           |

Data are presented as number (%), mean (SD) or median (25th, 75th percentile).

In multivariable regression model (R²=0.14, p=0.001) with age, sex, baseline HbA1c, baseline number of hypoglycemic episodes, the presence of microvascular and macrovascular complications, delta HbA1c and baseline MCS, only age (standardized beta = –0.17, 95% CI –0.29 to –0.07) and baseline MCS (standardized beta = –0.50, 95% CI –0.60 to –0.39) were significantly associated with improvements in MCS over 12 months (table 3).

DISCUSSION

This study describes the effect of FSL-FLM initiation on the prevalence rate of depressive disorders in persons with diabetes, estimated by the number of SF-12v2 MCS ≤45. After 6 and 12 months of FSL-FLM use, fewer persons had an MCS indicative of a depressive disorder as compared with baseline. The overall MCS also improved during follow-up, demonstrating improved mental well-being among FSL-FLM users.

Factors associated with depression and depressive disorders in persons with diabetes are female sex, higher HbA1c, non-white ethnicity, lower income, lower education level, a more sedentary lifestyle and presence of microvascular and macrovascular complications. In the present study, the depressive disorder rate was higher among women. Importantly, for men as well as women, the proportion of persons with a depressive disorder improved after FSL-FLM initiation. In contrast to our findings, Tyndall et al observed that initiation of FSL-FLM in persons with type 1 DM was associated with worsening of depression scores, measured by the HADS, although total diabetes distress levels were reduced. Of notice, newly elevated HADS depression scores after FSL-FLM commencement were related to greater social deprivation and lower income categories, a risk factor for depression and depressive disorders by itself. Our study population may be wealthier, since participants had to finance half of the costs of the FSL-FLM themselves, and—although hypothetical—this might account for the differences in study outcomes.

The observed improvement in mental health was associated with baseline MCS. Although the change in mental health was not significantly associated with the baseline number of hypoglycemic events, the link between both has been described in previous studies. Diabetes distress is associated with fear of hypoglycemia in persons with type 1 diabetes. Overend et al attributed a lower hypoglycemia frequency, a decrease in hypoglycemia severity and less fear of hypoglycemia among persons who initiated FSL-FLM as a key positive impact on well-being. Improvement of diabetes distress after FSL-FLM initiation correlated with improvement of glycemic control and hypoglycemia unawareness. These observations suggest that the negative impact of (fear of) hypoglycemas on mental health could be modified by FSL-FLM initiation, although this definitely is possible to hypothesize another explanation.

This study has limitations. First and foremost, a considerable number of persons included in the original FLARE-NL registry dropped out after 6 and 12 months, without reporting a reason for discontinuation. We hypothesize that the voluntary nature of participation in this registry and the longer duration of follow-up (as compared with other studies) might be of influence here.
Emerging technologies, pharmacology and therapeutics

Post-hoc analysis of baseline characteristics between persons with and without available data during follow-up demonstrated that persons without available data were more often male (57.4% vs 50.2%, \( p=0.017 \)) significantly younger (44.2 (±16.1) vs 48.2 (±15.8), \( p<0.001 \)) and had a higher HbA1c (66.1 (±15.1) vs 62.1 (±13.0), \( p<0.001 \)). Given the number of participants who did not fill in the questionnaires and the fact that data were patient reported, recall bias may be present. Since participants had to finance half of the costs of the FSL-FGM themselves, this will contribute to selection bias, as the selected participants probably will be more affluent than the average population with DM. We did not have access to FSL-FGM data (as data were gathered from 2016 to 2017) and therefore information such as time in range and other glycemic metrics is not available. Although the SF-12\(^{12} \) MCS is not a regular screening tool for depression and depressive disorders in persons with diabetes, the SF-12\(^{12} \) is considered as a valid generic instrument for measuring quality of life in this population.\(^{17} \)

### Table 2

|                          | Baseline (A) | 6 months (B) | 12 months (C) | \( P \) value A vs B | \( P \) value A vs C |
|--------------------------|--------------|--------------|--------------|----------------------|---------------------|
| MCS                      | 48.5±10.2    | 50.7±9.9     | 51.3±9.9     | <0.001               | <0.001              |
| n                        | 674          | 674          | 674          |                      |                     |
| MCS in women             | 47.1±10.4    | 48.9±9.8     | 49.6±10.2    | 0.03                 | 0.003               |
| n                        | 329          | 329          | 329          |                      |                     |
| MCS in men               | 49.9±9.9     | 52.4±9.7     | 52.9±9.2     | 0.001                | <0.001              |
| n                        | 345          | 345          | 345          |                      |                     |
| MCS in persons with a baseline MCS ≤45 | 36.9±6.0 | 43.4±9.4 | 44.2±9.9 | <0.001 | <0.001 |
| n                        | 235          | 235          | 235          |                      |                     |
| MCS in women with a baseline MCS ≤45 | 36.9±6.0 | 42.9±9.3 | 43.6±10.4 | <0.001 | <0.001 |
| n                        | 137          | 137          | 137          |                      |                     |
| MCS in men with a baseline MCS ≤45 | 37.0±6.0 | 44.0±9.6 | 45.2±9.2 | <0.001 | <0.001 |
| n                        | 98           | 98           | 98           |                      |                     |
| MCS in persons with a baseline MCS >45 | 54.8±5.5 | 54.6±7.6 | 55.1±7.4 | 0.87 | 0.87 |
| n                        | 439          | 439          | 439          |                      |                     |
| MCS in persons with type 1DM | 48.3±10.3 | 50.6±10.0 | 51.5±9.9 | <0.001 | <0.001 |
| n                        | 527          | 527          | 527          |                      |                     |
| MCS in persons with type 2DM | 48.5±10.2 | 50.4±9.7 | 50.5±9.4 | 0.49 | 0.46 |
| n                        | 98           | 98           | 98           |                      |                     |
| MCS in persons with an HbA1c ≤53 mmol/mol | 48.4±10.5 | 51.7±10.0 | 51.9±9.9 | 0.005 | 0.004 |
| n                        | 176          | 176          | 176          |                      |                     |
| MCS in persons with an HbA1c >53 mmol/mol | 48.6±10.1 | 50.4±9.8 | 51.2±9.8 | 0.01 | 0.001 |
| n                        | 497          | 497          | 497          |                      |                     |
| MCS in persons with HbA1c >64 mmol/mol | 48.9±10.2 | 50.1±9.9 | 51.1±10.3 | 0.36 | 0.04 |
| n                        | 251          | 251          | 251          |                      |                     |

Data are presented as mean±SD.

DM, diabetes mellitus; FSL-FGM, FreeStyle Libre flash glucose monitoring.

### Table 3

|                          | Standardized beta | \( P \) value |
|--------------------------|-------------------|--------------|
| Age                      | −0.17 (−0.29 to −0.07) | 0.001        |
| Male sex                 | −0.02 (−0.31 to 0.29) | 0.51         |
| Baseline HbA1c, mmol/mol | 0.02 (−0.11 to 0.14) | 0.80         |
| Number of hypoglycemic events past 6 months | −0.11 (−0.23 to 0.01) | 0.08         |
| Macrovascular complications | −0.08 (−0.42 to 0.27) | 0.66         |
| Microvascular complications | −0.10 (−0.43 to 0.13) | 0.38         |
| Delta of HbA1c, mmol/mol | −0.01 (−0.15 to 0.12) | 0.86         |
| Baseline MCS             | −0.50 (−0.60 to −0.39) | <0.001       |

Standardized beta regression coefficients are presented with 95% CIs.

MCS, Mental Component Score.
FSL-FGM are lacking to date, this study provides some information to fill this gap. Nevertheless, our findings should be interpreted with caution and its clinical relevance has to be proven in future studies.

CONCLUSIONS

The observed outcomes suggest that the depressive disorder rate among persons with diabetes is reduced after longer term FSL-FGM use, as compared with the period preceding FSL-FGM commencement.

Acknowledgements

We thank all participants for allowing us to use their data for the study and Jeanette Braakman and Marion Fokkert for data collection.

Contributors

JJB—statistical analysis, interpretation of data, writing the manuscript. AL—design, interpretation of data, writing the manuscript. JLF—statistical analysis, interpretation of data, and critically reviewing the manuscript. HLGB—design, critically reviewing the manuscript. PRvdO—design, interpretation of data, critically reviewing the manuscript, guarantor. All authors approved the final version of the manuscript.

Funding

The FLARE-NL registry was funded by an unconditional grant (number 2699) from the Stichting Achmea Gezondheidszorg (SAG). The SAG is an innovation fund of health insurance company ZilverenKruis.

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

This study involves human participants and was approved by the Medical Ethical Committee of Isala (Zwolle, The Netherlands) (METC 16.0346). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available upon reasonable request and with permission by the authors.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Annel Lameijer http://orcid.org/0000-0003-2407-3370
Jose L Flores Guerrero http://orcid.org/0000-0002-6094-2206
Peter R van Dijk http://orcid.org/0000-0002-9702-6551

REFERENCES

1 Ang E, Lee ZX, Moore S, et al. Flash glucose monitoring (FGM): a clinical review on glycaemic outcomes and impact on quality of life. J Diabetes Complications 2020;34:107559.
2 Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care 2019;7:e000809.
3 Lameijer A, Fokkert MJ, Edens MA, et al. Two-Year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6). BMJ Open Diabetes Res Care 2021;9:e002124.
4 Evans M, Welsh Z, Ells S, et al. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther 2020;11:83–90.
5 Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of British clinical Diabetologists (ABCD) nationwide audit. Diabetes Care 2020;43:215–63.
6 Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012;142 Suppl:S8–21.
7 Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol 2019;56:631–50.
8 Trief PM, Xing D, Foster NC, et al. Depression in adults in the TID exchange clinic registry. Diabetes Care 2014;37:1563–72.
9 Lustman PJ, Anderson PJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934–42.
10 Holt Rig, de Groot M, Golden SH. Diabetes and depression. Curr Diab Rep 2014;14:491.
11 Deshmukh H, Wilmot EG, Gregory R, et al. Predictors of diabetes-related distress before and after FreeStyle Libre-1 use: lessons from the association of British clinical Diabetologists nationwide study. Diabetes Obes Metab 2021;23:2261–8.
12 Al Hayek AA, Robert AA, Al Dawish MA. Effectiveness of the Freestyle Libre flash glucose monitoring system on diabetes distress among individuals with type 1 diabetes: a prospective study. Diabetes Ther 2020;11:927–37.
13 Tyrndal V, Stimson RH, Zammitt NN, et al. Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 2019;62:1349–56.
14 Fokkert MJ, Daman A, van Dijk PR, et al. Use of FreeStyle Libre flash monitor register in the Netherlands (FLARE-NL1): patient experiences, satisfaction, and cost analysis. Int J Endocrinol 2019;2019:1–6.
15 Vilagut G, Forero CG, Pinto-Meza A, et al. The mental component of the short-form 12 health survey (SF-12) as a measure of depressive disorders in the general population: results with three alternative scoring methods. Value Health 2013;16:564–73.
16 Gill SC, Butterworth P, Gehlan D, et al. Validity of the mental health component scale of the 12-item short-form health survey (MCS-12) as measure of common mental disorders in the general population. Psychiatry Res 2007;152:63–71.
17 Kathe N, Hayes CJ, Bhandari NR, et al. Assessment of reliability and validity of SF-12v2 among a diabetic population. Value Health 2018;21:432–40.
18 Ware J, Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.
19 Rajput R, Gehlawat P, Sehgal D, et al. Prevalence and predictors of depression and anxiety in patients of diabetes mellitus in a tertiary care center. Indian J Endocrinol Metab 2016;20:746–51.
20 Overend L, Simpson E, Grimwood T. Qualitative analysis of patient responses to the ABCD FreeStyle Libre audit questionnaire. Practical Diabetes 2019;36:45–50.